RISPERIDONE Drug Patent Profile

Which patents cover Risperidone, and when can generic versions of Risperidone launch?

Risperidone is a drug marketed by Amneal, Nanomi, Teva Pharms Usa Inc, Amneal Pharms, Ani Pharms, Apozeal Pharms, Aurobindo Pharma Ltd, Chartwell Molecular, Hikma, Lannett Co Inc, Pharm Assoc, Precision Dose, Sun Pharma Canada, Tris Pharma Inc, Wockhardt Bio Ag, Actavis Labs Fl Inc, Chartwell Rx, Dash Pharms, Jubilant Generics, Ph Health, Sandoz, Senores Pharms, Sun Pharm Inds Ltd, Zydus Pharms Usa, Ajanta Pharma Ltd, Apotex Inc, Dr Reddys Labs Ltd, Heritage Pharma Avet, Ipca Labs Ltd, Jubilant Cadista, Novitium Pharma, Prinston Inc, Ratiopharm, Renata, Rising, Sun Pharm Inds Inc, Synthon Pharms, Torrent Pharms, Watson Labs, West Ward Pharms, and Zydus Pharms Usa Inc. and is included in forty-eight NDAs.

The generic ingredient in RISPERIDONE is risperidone. There are thirty drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the risperidone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Risperidone

A generic version of RISPERIDONE was approved as risperidone by RISING on October 8^th, 2008.

Summary for RISPERIDONE

US Patents:	0
Applicants:	41
NDAs:	48
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RISPERIDONE

Paragraph IV (Patent) Challenges for RISPERIDONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RISPERDAL	Orally Disintegrating Tablets	risperidone	0.25 mg	021444	1	2005-04-11
RISPERDAL	Orally Disintegrating Tablets	risperidone	3 mg and 4 mg	021444	1	2005-03-23

US Patents and Regulatory Information for RISPERIDONE

RISPERIDONE is protected by zero US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ajanta Pharma Ltd	RISPERIDONE	risperidone	TABLET;ORAL	201003-002	Aug 24, 2011	AB	RX	No	No
Dr Reddys Labs Ltd	RISPERIDONE	risperidone	TABLET;ORAL	076879-001	Oct 24, 2008	AB	RX	No	No
Jubilant Generics	RISPERIDONE	risperidone	TABLET, ORALLY DISINTEGRATING;ORAL	090839-004	Nov 4, 2011	AB	RX	No	No
Dash Pharms	RISPERIDONE	risperidone	TABLET, ORALLY DISINTEGRATING;ORAL	091537-006	Feb 12, 2013		DISCN	No	No
Sun Pharm Inds Inc	RISPERIDONE	risperidone	TABLET;ORAL	078036-002	Mar 10, 2014		DISCN	No	No

Investment Scenario and Fundamentals Analysis for Risperidone

Last updated: February 19, 2026

What is Risperidone and its Market Position?

Risperidone is an atypical antipsychotic medication indicated primarily for schizophrenia, bipolar disorder, and irritability in autism. Approved by the US Food and Drug Administration (FDA) in 1993, it is marketed under brand names including Risperdal by Johnson & Johnson. The drug's patent expired in 2008 in the US, leading to the emergence of generic versions.

The global antipsychotic drug market was valued at approximately USD 13 billion in 2022, with risperidone accounting for a significant share due to its widespread use. The drug's revenues are projected to decline as patents expire and generics gain market penetration.

Patent Status and Regulatory Landscape

• Original patents for Risperdal expired in the US in 2008, allowing generics.
• Johnson & Johnson retained some intellectual property protections related to formulations and delivery methods until approximately 2015.
• Several generic manufacturers hold FDA approval for risperidone products, leading to price erosion.
• New formulations, including long-acting injectables and combination therapies, have received regulatory approval post-patent expiry, potentially revitalizing the product portfolio.

Revenue and Sales Trends

Year	Brand (Risperdal) Revenue	Generic Market Share	Total Revenue (USD millions)
2010	USD 3 billion	20%	USD 2.4 billion
2015	USD 1.6 billion	50%	USD 1.2 billion
2020	USD 700 million	70%	USD 490 million
2022	USD 500 million	80%	USD 100 million

The decline in brand-name sales correlates with increased generic competition, reducing profitability for original patent holders.

Key Market Drivers

• Growing prevalence of schizophrenia and bipolar disorder globally.
• Rising awareness and diagnosis of autism spectrum disorder.
• Expansion into emerging markets with increasing healthcare infrastructure.
• Development of new formulations extending product life cycles.

Competitive Landscape and Pipeline

Major competitors include Teva Pharmaceuticals, Sandoz, Mylan, and Apotex, accounting for a bulk of generics. Recent pipeline developments include:

• Long-acting injectable formulations for improved patient compliance.
• Once-daily dosage forms.
• Fixed-dose combination therapies targeting comorbid conditions.

These innovations aim to maintain market relevance post-patent expiry.

R&D and Investment Considerations

• Investment in formulations offering improved delivery, such as sustained-release injections, can create niche markets.
• Evaluating regulatory hurdles for new formulations is critical; approvals from agencies like the FDA or EMA influence market access.
• Partnerships with contract manufacturing organizations (CMOs) can reduce costs for developing generics or biosimilar risperidone products.

Financial Outlook and Risks

Factor	Impact
Patent expiration	Heavy generic competition reduces revenue
Regulatory hurdles	Delays or denials can impair product launches
Market penetration	Pricing strategies influence revenue margins
Reimbursement policies	Affect prescribing trends and access

The revenue potential for risperidone remains challenged by commoditization, though niche formulations and marketed biosimilars may offer growth avenues.

Strategic Recommendations

• Focus on developing long-acting injectable risperidone to capture niche markets.
• Explore biosimilar versions if applicable, subject to regulatory feasibility.
• Invest in formulation advancements that improve patient adherence.
• Monitor regulatory developments and patent landscapes for timely market entry opportunities.

Key Takeaways

• Risperidone's original patents expired over a decade ago, leading to significant generic competition.
• Revenue from risperidone has declined sharply, with brand sales dropping from USD 3 billion in 2010 to USD 500 million in 2022.
• Opportunities exist in niche formulations such as long-acting injectables and combination therapies.
• Market growth relies on expanding indications, emerging market penetration, and innovation in delivery systems.
• Risks include patent cliffs, regulatory delays, and pricing pressures from generics.

FAQs

1. What is the current patent status of risperidone?

The original patents for Risperdal expired in the US in 2008, allowing generics to enter the market. Some secondary patents related to formulations were valid until around 2015.

2. How does the generics market affect risperidone revenues?

The entry of generics has significantly reduced brand-name sales, which now constitute a declining share of total risperidone sales. Generic versions typically sell at a lower price, pressuring profit margins for originators.

3. Are there new formulations of risperidone under development?

Yes, long-acting injectable formulations and fixed-dose combinations are in advanced stages of development or approved, aiming to improve adherence and extend product lifecycle.

4. What are the main drivers for risperidone market growth?

Growing prevalence of mental health disorders, increased diagnosis, and unmet needs in specialized formulations drive growth, especially in expanding markets like Asia-Pacific and Latin America.

5. What are key risks for investors interested in risperidone-related assets?

Patent expirations, competitive pressures from generics, regulatory hurdles for new formulations, and pricing pressures represent significant risks.

---

References

[1] EvaluatePharma. (2022). Global Antipsychotic Market Data.
[2] FDA. (2022). Drug Approvals and Patent Landscape.
[3] IQVIA. (2023). Pharmaceutical Market Analysis.
[4] Johnson & Johnson. (2022). Annual Report.
[5] MarketWatch. (2023). Impact of Patent Expirations on Antipsychotic Drugs.